Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8465860 | 0.78 | HTR2A (0.38) | SLC6A4CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL10580002 | 0.69 | LMNA (0.60) | SLC6A4CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL28858474 | 0.65 | HTR2A (0.40) | HTR2AALDH1A1 | |
| SCHEMBL29048894 | 0.63 | SLC6A2 (0.33) | SLC6A4CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL25159737 | 0.63 | IGF1R (0.45) | HTR2A | |
| SCHEMBL3721488 | 0.63 | IGF1R (0.45) | HTR2A | |
| SCHEMBL2238553 | 0.63 | IGF1R (0.45) | HTR2A | |
| SCHEMBL28429811 | 0.63 | SLC6A4 (0.38) | SLC6A4CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL8250967 | 0.63 | SLC6A4 (0.38) | SLC6A4CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL7634181 | 0.63 | SLC6A2 (0.47) | SLC6A4CHRM2HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395259-A4 | URAZOLE COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1395259-A2 | URAZOLE COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6673825-B2 | ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| US-20030013745-A1 | Urazole compounds useful as anti-inflammatory agents | CEREP SA (FR) | 2003-01-16 | — | — | US | disclosed |
| WO-2002094186-A2 | URAZOLE COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013745-A1 | Urazole compounds useful as anti-inflammatory agents | TPMT, IL4, IL5 | SLC6A4 2998/4885CHRM2 1924/4885HTR1A 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.